Pictet-Biotech I dy GBP

Name
Pictet-Biotech I dy GBP
Manager
Pictet Asset Management (Europe) SA
Type
SICAV
ISIN
LU0448836352
Sector
LC00000063
Launched
10/09/2009
OCF
1.2 %
Risk Rating
3
3 Year Sharpe
0.17
3 Year Alpha
-4.38
Yield
0 %
Benchmark
MSCI World NR USD
This compartment aims to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The compartment will invest at least two-thirds of its total assets or wealth in equities issued by companies operating in this sector. To capitalise on particularly innovative projects in the drugs industry, the Biotech Compartment may invest up to 10% of its net assets in Private Equity and/or unlisted securities.
Holding%
Celgene Corp9.27 %
Gilead Sciences Inc7.35 %
Amgen Inc5.84 %
Biogen Inc5.80 %
Alexion Pharmaceuticals Inc5.06 %
Regeneron Pharmaceuticals Inc4.64 %
Vertex Pharmaceuticals Inc4.31 %
Incyte Corp3.76 %
Biomarin Pharmaceutical Inc3.29 %
Tesaro Inc2.53 %
Region%
United States96.26 %
Sector%
Healthcare100.00 %
Name
Pictet Asset Management (Europe) SA
Address
L-1855, Luxembourg, Luxembourg
UCITS
Yes
Legal Structure
SICAV

Managers

Tazio Storni

Joined 05/26/2016

Lydia Haueter

Joined 05/26/2016

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.